<DOC>
	<DOCNO>NCT00521430</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy donor stem cell transplant help stop growth cancer abnormal cell . It also help stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving cyclosporine methotrexate transplant may stop happen . PURPOSE : This clinical trial study side effect well donor stem cell transplant work give condition therapy treat patient hematologic cancer , recurrent metastatic solid tumor , disease .</brief_summary>
	<brief_title>Donor Stem Cell Transplant After Conditioning Therapy Treating Patients With Hematologic Cancer , Recurrent Metastatic Solid Tumor , Other Disease</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety efficacy non-T-cell deplete , HLA-haploidentical relate donor hematopoietic stem cell transplantation reduced-intensity condition regimen comprise busulfan , fludarabine phosphate , anti-thymocyte globulin , methylprednisolone patient hematologic cancer , recurrent metastatic solid tumor , disease . OUTLINE : - Reduced-intensity conditioning regimen : Patients receive busulfan IV 4 time daily day -7 -6 ; fludarabine phosphate IV 30 minute day -7 -2 ; methylprednisolone IV 30 minute follow anti-thymocyte globulin IV 4 hour day -4 -1 . - Donor hematopoietic stem cell transplantation : Patients receive donor peripheral blood stem cell IV 1 hour day 0 1 . - Graft-versus-host disease ( GVHD ) prophylaxis : Patients receive cyclosporine IV 2-4 hour orally twice daily begin day -1 continue day 60 , follow taper absence GVHD . Patients also receive methotrexate IV day 2 , 4 , 7 , 12 . After transplant , patient follow periodically .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 following : Highrisk acute leukemia , include follow : Refractory acute leukemia Acute leukemia beyond first remission Acute leukemia first remission poor prognostic feature ( e.g. , chromosomal change suggest poor prognosis ) Chronic myelogenous leukemia second chronic , accelerate , blastic phase Severe aplastic anemia responsive immunosuppressive therapy Myelodysplastic syndrome , include follow : Refractory anemia ( RA ) RA ring sideroblast severe cytopenia RA excess blast ( RAEB ) RAEB transformation Chronic myelomonocytic leukemia Refractory relapse nonHodgkin Hodgkin lymphoma Multiple myeloma Biopsy proven measurable solid tumor meeting 1 follow criterion : Recurrent disease primary treatment deem incurable standard treatment Metastatic disease know standard therapy potentially curative definitely capable extend life expectancy exist Must related HLAhaploidentical mismatch ( 3/6 few locus ) donor available PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % Bilirubin &lt; 2.0 mg/dL AST &lt; 3 time upper limit normal Creatinine &lt; 2.0 mg/dL Ejection fraction &gt; 40 % MUGA PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>recurrent childhood grade III lymphomatoid granulomatosis</keyword>
	<keyword>childhood diffuse large cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>childhood immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>childhood nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>aplastic anemia</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>Waldenstr√∂m macroglobulinemia</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>cutaneous B-cell non-Hodgkin lymphoma</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
</DOC>